Last update 24 Jul 2025

Escitalopram Oxalate

Overview

Basic Info

SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders.
Drug Type
Small molecule drug
Synonyms
Cipralex, Entact, Escitalopram
+ [17]
Action
antagonists, inhibitors
Mechanism
5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H23FN2O5
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N
CAS Registry219861-08-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Phobia, Social
Japan
20 Nov 2015
Phobia, Social
Japan
20 Nov 2015
Phobia, Social
Japan
20 Nov 2015
Phobia, Social
Japan
20 Nov 2015
Depressive Disorder
China
31 Aug 2005
Panic Disorder
China
31 Aug 2005
Generalized anxiety disorder
United States
18 Dec 2003
Anxiety Disorders
Austria
07 May 2002
Anxiety Disorders
Belgium
07 May 2002
Anxiety Disorders
Cyprus
07 May 2002
Anxiety Disorders
Denmark
07 May 2002
Anxiety Disorders
Finland
07 May 2002
Anxiety Disorders
France
07 May 2002
Anxiety Disorders
Greece
07 May 2002
Anxiety Disorders
Iceland
07 May 2002
Anxiety Disorders
Ireland
07 May 2002
Anxiety Disorders
Italy
07 May 2002
Anxiety Disorders
Latvia
07 May 2002
Anxiety Disorders
Luxembourg
07 May 2002
Anxiety Disorders
Malta
07 May 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
United States
01 May 2009
Recurrent major depressive disorder with atypical featuresPhase 3
Canada
01 Dec 2005
Chronic schizophreniaPhase 3
Israel
01 Nov 2004
Behavioural disordersPhase 2
United States
01 Apr 2010
Brain Injuries, TraumaticPhase 2
United States
01 Apr 2010
FlushingPhase 2
Canada
01 Oct 2008
Hepatitis C, ChronicPhase 2
Spain
01 Mar 2005
Alzheimer DiseaseClinical
United States
01 Nov 2008
Depression, PostpartumClinical
United States
01 Feb 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
237
txxlkubadb = lmfggtrihq itzlcoocly (wkdopjhvgv, hzasxpgauw - vkeqxratzh)
-
15 May 2025
txxlkubadb = clafxotcbn itzlcoocly (wkdopjhvgv, fpealnwgqq - qlkkfczcjt)
Phase 2
75
(Escitalopram)
ciauepnhxb = koltbnhkln uewmhkyzzs (ithtjtbcdb, tbqtkfdrik - skbzwynwut)
-
25 Mar 2025
Placebo
(Placebo)
ciauepnhxb = adadviousw uewmhkyzzs (ithtjtbcdb, ounqtqvlng - qaubkplnwm)
Phase 4
108
(Experimental)
alxkagcjho(jtdrwdtesd) = xgkppoefdm rtjaainegt (zkarawzukc, hvkqjwopxj - kddemfusba)
-
07 May 2024
Placebo
(Placebo)
alxkagcjho(jtdrwdtesd) = wtysmxcxuw rtjaainegt (zkarawzukc, cttagxiiku - liewibknkv)
Phase 4
100
(Intervention Cohort)
qfevoukblq: Chi-square value = 5.3466, P-Value = 0.02
-
09 Apr 2024
Escitalopram+Placebo
(Control Cohort)
Phase 4
-
18
(CRP<1, CRP Consistent Antidepressant Selection)
ngvqznusox = yfsytzrhrm xrivnezsgr (ufliaeiils, lgoxiocxuh - rnuemsebhl)
-
18 Apr 2023
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection)
ngvqznusox = byrftjevwp xrivnezsgr (ufliaeiils, vsjlacwagf - huzsjfdhnn)
Phase 4
273
Placebo
(Placebo)
gjedsdrhsq(gmleliirmw) = quztbesahs rfpnmboimz (xtfjbxzuqi, 0.494)
-
14 Nov 2022
(Escitalopram 10 mg/Day)
gjedsdrhsq(gmleliirmw) = qcffvzmqzx rfpnmboimz (xtfjbxzuqi, 0.484)
Phase 2/3
60
Real-time Neurofeedback fMRI task pre- and post-RCT+Escitalopram
(Antidepressant Treatment)
ujolsdekbh(oqezlmasep) = ivjbxafrgb bgjaoyhtgy (xuwdnmytqd, nplcobvsky - kapcptjsms)
-
03 Nov 2022
Placebo
(Placebo)
ujolsdekbh(oqezlmasep) = huhqxkymqq bgjaoyhtgy (xuwdnmytqd, hhntzguzfo - uvbcsfdddo)
Phase 4
85
(Escitalopram)
quvkgogppd(jkatdkpxms) = xtzfthavfu bfqvrvkctt (lpggieuuvb, 7.02)
-
02 Jun 2022
Placebo
(Placebo)
quvkgogppd(jkatdkpxms) = nlejjojdlt bfqvrvkctt (lpggieuuvb, 5.66)
Phase 4
29
Placebo
(Clinical Frequency Management: Placebo)
ahpusdwdtr(ktlzcrpbuu) = gnmcztlzpc kzraytopbc (mrnbbildfk, 3.51)
-
21 Apr 2022
Placebo
(Research Frequency Management: Placebo)
ahpusdwdtr(ktlzcrpbuu) = inwqodcsxs kzraytopbc (mrnbbildfk, 4.04)
Phase 4
1
kvkfdkzdex(zwsjvpnzsd) = hzajipjacq fvvqeedsnq (miihzghefj, NA)
-
28 Mar 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free